620 related articles for article (PubMed ID: 18511928)
1. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
Comoglio PM; Giordano S; Trusolino L
Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
[TBL] [Abstract][Full Text] [Related]
2. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
3. Molecular cancer therapy: can our expectation be MET?
Migliore C; Giordano S
Eur J Cancer; 2008 Mar; 44(5):641-51. PubMed ID: 18295476
[TBL] [Abstract][Full Text] [Related]
4. Targeting the MET oncogene in cancer and metastases.
Stella GM; Benvenuti S; Comoglio PM
Expert Opin Investig Drugs; 2010 Nov; 19(11):1381-94. PubMed ID: 20868306
[TBL] [Abstract][Full Text] [Related]
5. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
Matsumoto K; Nakamura T; Sakai K; Nakamura T
Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
[TBL] [Abstract][Full Text] [Related]
7. Progress in cancer therapy targeting c-Met signaling pathway.
Jung KH; Park BH; Hong SS
Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
[TBL] [Abstract][Full Text] [Related]
8. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
Liu X; Newton RC; Scherle PA
Trends Mol Med; 2010 Jan; 16(1):37-45. PubMed ID: 20031486
[TBL] [Abstract][Full Text] [Related]
9. Small molecule c-Met kinase inhibitors: a review of recent patents.
Porter J
Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
[TBL] [Abstract][Full Text] [Related]
10. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer.
Toschi L; Jänne PA
Clin Cancer Res; 2008 Oct; 14(19):5941-6. PubMed ID: 18829470
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.
Weinstein IB; Joe AK
Nat Clin Pract Oncol; 2006 Aug; 3(8):448-57. PubMed ID: 16894390
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase.
Albrecht BK; Harmange JC; Bauer D; Berry L; Bode C; Boezio AA; Chen A; Choquette D; Dussault I; Fridrich C; Hirai S; Hoffman D; Larrow JF; Kaplan-Lefko P; Lin J; Lohman J; Long AM; Moriguchi J; O'Connor A; Potashman MH; Reese M; Rex K; Siegmund A; Shah K; Shimanovich R; Springer SK; Teffera Y; Yang Y; Zhang Y; Bellon SF
J Med Chem; 2008 May; 51(10):2879-82. PubMed ID: 18426196
[TBL] [Abstract][Full Text] [Related]
13. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
Koeppen H; Rost S; Yauch RL
J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
[TBL] [Abstract][Full Text] [Related]
14. Expression of hepatocyte growth factor and the proto-oncogenic receptor c-Met in canine osteosarcoma.
Fieten H; Spee B; Ijzer J; Kik MJ; Penning LC; Kirpensteijn J
Vet Pathol; 2009 Sep; 46(5):869-77. PubMed ID: 19429984
[TBL] [Abstract][Full Text] [Related]
15. MET receptor tyrosine kinase as a therapeutic anticancer target.
Stellrecht CM; Gandhi V
Cancer Lett; 2009 Jul; 280(1):1-14. PubMed ID: 19100682
[TBL] [Abstract][Full Text] [Related]
16. c-MET kinase inhibitors: a patent review (2011 - 2013).
Zhu K; Kong X; Zhao D; Liang Z; Luo C
Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
[TBL] [Abstract][Full Text] [Related]
17. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
[TBL] [Abstract][Full Text] [Related]
18. met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable pre-clinical model of human osteosarcoma.
De Maria R; Miretti S; Iussich S; Olivero M; Morello E; Bertotti A; Christensen JG; Biolatti B; Levine RA; Buracco P; Di Renzo MF
J Pathol; 2009 Jul; 218(3):399-408. PubMed ID: 19402129
[TBL] [Abstract][Full Text] [Related]
19. A new Met inhibitory-scaffold identified by a focused forward chemical biological screen.
Patané S; Pietrancosta N; Hassani H; Leroux V; Maigret B; Kraus JL; Dono R; Maina F
Biochem Biophys Res Commun; 2008 Oct; 375(2):184-9. PubMed ID: 18703015
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.
Finisguerra V; Prenen H; Mazzone M
Oncogene; 2016 Oct; 35(42):5457-5467. PubMed ID: 26996670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
